T-knife Therapeutics

T-knife Therapeutics is a cutting-edge biopharmaceutical company focused on revolutionizing cancer treatment through the development of innovative therapeutics. T-knife Therapeutics specializes in T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality with the potential to deliver transformative results for patients battling solid tumors.

T-knife Therapeutics' groundbreaking approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine. This platform produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity, ensuring targeted and effective therapies. T-knife Therapeutics is dedicated to advancing a robust portfolio of TCR-T product candidates targeting areas with significant unmet medical needs, including cancer testis antigens, oncoviral antigens, and commonly shared tumor-driving neoantigens.

The primary address for T-knife Therapeutics is in San Francisco, US, with an additional location at Robert-Rössle-Str. 10, Berlin, Berlin 13125, DE. The team at T-knife Therapeutics is constantly innovating to improve cancer treatment outcomes. We invite the management team at T-knife Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further enhance their commercial development.